London: Tuesday, December 31, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
| 1. | Name of applicant: | Hutchison China MediTech Limited | ||
| 2. | Name of scheme: | (a) | Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 (“2005 HCML Share Option Scheme”) | |
| (b) | Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 (“2015 HCML Share Option Scheme”) | |||
| 3. | Period of return: | From June 29, 2019 to December 28, 2019 | ||
| 4. |
Balance under scheme from previous return:
|
(a) | 2005 HCML Share Option Scheme: 2,067,910 ordinary shares of US$0.1 each | |
| (b) | 2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each | |||
| 5. |
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
|
(a) | 2005 HCML Share Option Scheme: Nil | |
| (b) | 2015 HCML Share Option Scheme: Nil | |||
| 6. |
Number of securities issued/allotted under scheme during period:
|
(a) | 2005 HCML Share Option Scheme: 329,000 | |
| (b) | 2015 HCML Share Option Scheme: Nil | |||
| 7. |
Balance under scheme not yet issued/allotted at end of the period:
|
(a) | 2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US$0.1 each | |
| (b) | 2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each | |||
| 8. |
Number and class of securities originally listed and the date of admission:
|
25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company’s previous block admission schemes following the Company’s share subdivision which took effect on May 30, 2019) | ||
| 9. | Total number of securities in issue at the end of the period: | 666,906,450 ordinary shares of US$0.1 each | ||
| Name of contact: | Christian Hogg | |||
| Address of contact: | Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong | |||
| Telephone number of contact: | +852 2121 8200 | |||
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 490 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.
Mark Lee, Senior Vice President, Corporate Finance & Development
+852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development
+1 (973) 567 3786
David Dible, Citigate Dewe Rogerson
+44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout
+1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas – Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China – Joseph Chi Lo, Brunswick
+852 9850 5033 (Mobile)
jlo@brunswickgroup.com
Hong Kong & Asia ex-China – Zhou Yi, Brunswick
+852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China – Sam Shen, Edelman
+86 1367 179 1029 (Mobile)
sam.shen@edelman.com
Atholl Tweedie, Panmure Gordon (UK) Limited
+44 (20) 7886 2500